Saturday 17 October 2026 Export BTAIQ’s income statement to Excel — free account

BioXcel Therapeutics, Inc.

BTAIQ Healthcare Drug Manufacturers Specialty & Generic

BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024. In the quarter to June 2026, revenue grew 51.7%, EPS grew 80.0%, free cash flow grew 51.5% and total debt fell 3.90%, each against the same quarter a year earlier.

0.03 0.00 0.00%

Follow BTAIQ

Alert me

Market cap: $2.3M
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: 2/9
Altman Z: −26.30
Beneish M: −0.61
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	4	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.31

Revenue 0.74

Net Income (70.86)

Free Cash Flow (50.90)

Net Debt 90.65

Current Ratio 0.21

Debt/Equity (0.90)

P/E ratio 0.00

Fwd P/E (0.42)

P/S ratio 1.23

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 52.88%

Next Y EPS Growth 20.74%

Next Y revenue growth 19.92%

Next 5Y EPS Growth 48.34%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.36%

10-year low 10-year high

EV/Sales against its own 10 years 88.89%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	65	30	29	14
Receivables	0	0	0	0
Inventory	2	1	1	0
Other	2	1	11	11
	72	37	45	29

	2023	2024	2025	Q'26
Payables	14	16	15	19
ST’ Debt	—	—	25	104
Other	0	0	10	10
	27	22	54	137

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	19.63%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	1
’24	1	1	0	0	2
’23	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(6)	—	—	—
’25	(12)	(13)	(19)	(14)	(58)
’24	(18)	(23)	(16)	(15)	(72)
’23	(52)	(38)	(38)	(27)	(155)
’22	(32)	(33)	(31)	(39)	(135)
’21	(20)	(22)	(20)	(20)	(82)
’20	(12)	(15)	(19)	(20)	(66)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(6)	—	—	—
’25	(12)	(13)	(19)	(14)	(58)
’24	(18)	(23)	(16)	(15)	(72)
’23	(52)	(38)	(38)	(27)	(155)
’22	(33)	(33)	(31)	(39)	(135)
’21	(20)	(22)	(20)	(20)	(83)
’20	(12)	(15)	(19)	(21)	(67)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.54)	(0.49)	—	—	—
’25	(1.50)	(2.45)	(2.18)	(0.58)	(5.73)
’24	(13.92)	(3.36)	(5.12)	(3.57)	(23.51)
’23	(29.44)	(29.28)	(27.52)	(12.16)	(98.40)
’22	(17.92)	(21.60)	(23.84)	(31.20)	(94.72)
’21	(17.28)	(17.76)	(15.36)	(14.88)	(64.80)
’20	(12.64)	(16.96)	(17.12)	(13.92)	(60.64)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	38.56	53.28	191.20	299.44	140.72	35.68	4.80	1.17	Analyst estimates 2026–2028 Powerpack
	High	—	—	236.64	236.80	1,144.00	1,083.84	393.12	546.00	66.72	9.26
People
People	Employees	—	6	18	24	50	89	183	74	37	29
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.06	0.02
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	0	1	2	1
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	94.67	8.70	5.43	74.45
	EBT	(2)	(5)	(19)	(33)	(82)	(107)	(166)	(179)	(60)	(70)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	(44,201.87)	(12,974.86)	(2,630.14)	(10,887.38)
	Net income	(2)	(5)	(19)	(33)	(82)	(107)	(166)	(179)	(60)	(70)
	Depreciation	—	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.21	0.76	0.89	0.05
	Earnings	(3.58)	(7.50)	(21.12)	(32.32)	(60.64)	(64.80)	(94.72)	(98.40)	(23.51)	(5.73)
	Cash flow	(2.18)	(3.63)	(14.83)	(26.62)	(48.96)	(49.84)	(77.30)	(85.12)	(28.41)	(4.72)
	Capex	(0.01)	0.00	(0.37)	(0.85)	(0.23)	(0.27)	(0.08)	(0.01)	0.00	0.00
	Free cash flow	(2.19)	(3.63)	(15.21)	(27.47)	(49.19)	(50.11)	(77.38)	(85.13)	(28.41)	(4.72)
	Book value	(0.55)	(1.62)	42.70	26.42	152.52	134.48	43.85	(31.03)	(36.73)	(7.82)
	Shares, m	1	1	1	1	1	2	2	2	3	12
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	0.00	61.86	6.69	30.42
	P/B	—	—	—	—	—	—	7.83	0.00	0.00	0.00
	EV/Sales	—	—	—	—	—	—	0.00	87.74	38.90	156.34
	EV/FCF	—	—	—	—	—	—	(3.70)	(0.78)	(1.22)	(1.74)
Cash, $m
Cash, $m	Operating cash flow	(1)	(2)	(14)	(27)	(66)	(82)	(135)	(155)	(72)	(58)
	Capex	0	—	0	(1)	0	0	0	0	—	—
	Free cash flow	(1)	(2)	(14)	(28)	(67)	(83)	(135)	(155)	(72)	(58)
Balance, $m
Balance, $m	Working capital	0	(1)	39	26	205	220	170	45	15	(9)
	Total debt	—	0	—	1	2	1	93	101	103	110
	Net debt	—	(1)	(43)	(31)	(211)	(232)	(100)	35	73	81
	Shareholders’ equity	0	(1)	39	27	207	222	77	(57)	(93)	(95)
Returns, %
Returns, %	ROA	(311.31)	(666.52)	(85.83)	(82.48)	(64.11)	(46.55)	(74.45)	(128.10)	(106.39)	(167.91)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	324.66	695.10	(101.67)	(100.23)	(70.35)	(49.93)	(111.08)	(1,766.94)	79.67	74.14

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GELS Gelteq Limited	$4.6M	—	—	—	—	−40.15% (below 0%: shrinking)	—	—	Compare
RDHL Redhill Biopharma Ltd.	$4.4M	— (loss-making)	— (loss-making)	−90.32% (below 0%: shrinking)	n/m	−107.31% (below 0%: shrinking)	(7.52%)	0.00%	Compare
YCBD cbdMD, Inc.	$4.0M	41.2×	— (loss-making)	+20.55% (above 0%: growing)	n/m	+34.80% (above 0%: growing)	54.69%	(20.36%)	Compare
AKAN Akanda Corp.	$3.5M	—	—	—	—	−472.01% (below 0%: shrinking)	(197.87%)	0.00%	Compare
PRFX PainReform Ltd.	$2.6M	— (loss-making)	— (loss-making)	—	n/m	+52.56% (above 0%: growing)	0.00%	0.00%	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	— (loss-making)	— (loss-making)	+51.67% (above 0%: growing)	n/m	+51.51% (above 0%: growing)	87.91%	(5,600.55%)
IMCC IM Cannabis Corp.	$2.2M	— (loss-making)	— (loss-making)	−40.28% (below 0%: shrinking)	n/m	−266.81% (below 0%: shrinking)	19.83%	(27.54%)	Compare
NEPTF Neptune Wellness Solutions Inc.	$1.6M	— (loss-making)	— (loss-making)	−37.75% (below 0%: shrinking)	n/m	+53.44% (above 0%: growing)	13.62%	(232.88%)	Compare
PTPI Petros Pharmaceuticals, Inc.	$1.0M	— (loss-making)	— (loss-making)	+1,070.55% (above 0%: growing)	n/m	+71.27% (above 0%: growing)	73.82%	0.00%	Compare
Median of peers	$3.0M	—	—	−37.75%	—	−2.68%	13.62%	0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

BioXcel Therapeutics, Inc. (BTAIQ) key facts

Concern: BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024.
BioXcel Therapeutics, Inc. (BTAIQ) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector.
As of October 16, 2026, BTAIQ traded at $0.03, a market capitalization of $2.3 million.
Return on equity was 74.1% and debt-to-equity -0.90.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −26.30 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.